Guggenheim Forecasts Strong Price Appreciation for BeOne Medicines (NASDAQ:ONC) Stock

BeOne Medicines (NASDAQ:ONC) had its price objective lifted by Guggenheim from $420.00 to $430.00 in a note issued to investors on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Guggenheim’s price objective indicates a potential upside of 23.47% from the company’s previous close.

A number of other research analysts have also weighed in on ONC. Leerink Partners raised their price objective on shares of BeOne Medicines from $364.00 to $367.00 and gave the company an “outperform” rating in a research note on Friday, May 15th. Nomura raised shares of BeOne Medicines to a “strong-buy” rating in a research report on Monday, July 27th. Truist Financial upped their target price on shares of BeOne Medicines from $413.00 to $416.00 and gave the stock a “buy” rating in a report on Tuesday, July 7th. JPMorgan Chase & Co. raised their price target on shares of BeOne Medicines from $415.00 to $425.00 and gave the company an “overweight” rating in a research report on Thursday, July 23rd. Finally, Zacks Research downgraded BeOne Medicines from a “strong-buy” rating to a “hold” rating in a research note on Friday, July 3rd. Two analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, BeOne Medicines has an average rating of “Moderate Buy” and a consensus target price of $400.00.

BeOne Medicines Price Performance

Shares of NASDAQ:ONC opened at $348.27 on Thursday. BeOne Medicines has a twelve month low of $253.95 and a twelve month high of $385.22. The stock’s 50 day moving average is $296.52 and its 200-day moving average is $308.89. The company has a quick ratio of 3.27, a current ratio of 3.40 and a debt-to-equity ratio of 0.17. The firm has a market capitalization of $38.21 billion, a price-to-earnings ratio of 61.32 and a beta of 0.49.

BeOne Medicines (NASDAQ:ONC) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $2.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.40 by $0.65. The business had revenue of $1.71 billion during the quarter, compared to the consensus estimate of $1.66 billion. BeOne Medicines had a net margin of 10.70% and a return on equity of 14.23%. Sell-side analysts forecast that BeOne Medicines will post 6.26 EPS for the current fiscal year.

Insider Buying and Selling at BeOne Medicines

In other BeOne Medicines news, COO Xiaobin Wu sold 1,484 shares of BeOne Medicines stock in a transaction on Monday, June 8th. The shares were sold at an average price of $269.37, for a total transaction of $399,745.08. Following the transaction, the chief operating officer directly owned 40 shares of the company’s stock, valued at $10,774.80. The trade was a 97.38% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO John Oyler sold 145,861 shares of the company’s stock in a transaction on Tuesday, July 14th. The stock was sold at an average price of $305.95, for a total transaction of $44,626,172.95. Following the completion of the sale, the chief executive officer owned 8,122 shares of the company’s stock, valued at approximately $2,484,925.90. The trade was a 94.73% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 345,561 shares of company stock worth $105,625,947. Company insiders own 6.19% of the company’s stock.

Institutional Investors Weigh In On BeOne Medicines

A number of institutional investors have recently added to or reduced their stakes in ONC. Bank of America Corp DE purchased a new stake in BeOne Medicines in the 2nd quarter valued at about $67,657,000. Man Group plc bought a new position in shares of BeOne Medicines during the 2nd quarter worth approximately $59,031,000. BNP Paribas Financial Markets purchased a new position in shares of BeOne Medicines in the 2nd quarter worth approximately $38,337,000. First Trust Advisors LP boosted its stake in shares of BeOne Medicines by 91.9% in the 1st quarter. First Trust Advisors LP now owns 241,426 shares of the company’s stock worth $71,696,000 after buying an additional 115,601 shares during the last quarter. Finally, Qube Research & Technologies Ltd bought a new position in shares of BeOne Medicines in the second quarter valued at approximately $26,034,000. 48.55% of the stock is owned by institutional investors.

Key BeOne Medicines News

Here are the key news stories impacting BeOne Medicines this week:

• Positive Sentiment: Strong Q2 performance: BeOne reported adjusted earnings of $2.05 per share, topping the $1.40 consensus estimate, while revenue reached $1.71 billion versus expectations of $1.66 billion. The earnings beat reinforces confidence in the company’s oncology portfolio and profitability. BeOne Medicines Q2 earnings report
• Positive Sentiment: 2026 outlook raised: Management increased its full-year revenue forecast to approximately $6.6 billion-$6.8 billion, above Wall Street’s prior estimate of $6.5 billion, citing a 30% quarterly revenue surge. BeOne Medicines raises 2026 outlook
• Positive Sentiment: Analyst targets moved higher: TD Cowen raised its target to $454 and assigned a Buy rating; Guggenheim increased its target to $430, Truist lifted its target to $418, and Citizens JMP raised its target to $405. RBC made a modest reduction to $450 but retained an Outperform rating. Collectively, the updates indicate substantial implied upside from recent trading levels. Analyst price-target updates
• Positive Sentiment: Institutional buying: Bank of America, Man Group, BNP Paribas and other institutions recently established or expanded positions, suggesting continued professional-investor interest in ONC.
• Neutral Sentiment: Insider sale was tax-related: CFO Aaron Rosenberg sold 1,157 shares valued at about $362,000 to cover tax withholding from vested equity awards. The transaction is therefore a limited bearish signal. SEC insider transaction filing
• Negative Sentiment: Valuation risk: With a high earnings multiple and the stock trading below its 52-week high, investors may require continued rapid growth and execution to justify the current valuation.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.